Table 3.
Heterogeneity of NET biology, as indicated by PET. In G1 NET, the vast majority of lesions showed sole expression of SSTR2, as indicated by focal retention of [68Ga]DOTATOC (104 lesions), and only few (11 lesions) concurrent glucose use, as indicated by [18F]FDG-PET. No lesion was positive at [68Ga]Pentixafor PET indicating no CXCR4 expression. In G3 NET, the vast majority of lesions revealed various combinations of SSTR and CXCR4 expression with or without deregulated glucose use.
| G1 NET | [68Ga]DOTATOC | [18F]FDG | [68Ga]Pentixafor |
|---|---|---|---|
| [68Ga]DOTATOC | 104 | 11 | 0 |
| [18F]FDG | - | 0 | 0 |
| [68Ga]Pentixafor | - | - | 0 |
| G2 NET | [68Ga]DOTATOC | [18F]FDG | [68Ga]Pentixafor |
| [68Ga]DOTATOC | 107 | 10 | 3 |
| [18F]FDG | - | 3 | 3 |
| [68Ga]Pentixafor | - | - | 0 |
| G3 NET | [68Ga]DOTATOC | [18F]FDG | [68Ga]Pentixafor |
| [68Ga]DOTATOC | 0 | 11 | 12 |
| [18F]FDG | - | 47 | 56 |
| [68Ga]Pentixafor | - | - | 9 |
Since some lesions were positive for all three tracers, the sum of lesions can exceed the number given in the manuscript. [68Ga]DOTATOC = 68Ga-DOTA-D-Phe-Tyr3-octreotide, [18F]FDG = 18F-fluorodeoxy-glucose.